📊 PTCT Key Takeaways
Is Ptc Therapeutics, Inc.. (PTCT) a Good Investment?
PTC Therapeutics demonstrates exceptional revenue growth (114.5% YoY) with strong operational execution, approaching GAAP profitability at -1.0% net margin. However, negative stockholders' equity and negative operating/free cash flow create financial stress that must be resolved before initiating larger positions, despite adequate liquidity runway.
Ptc Therapeutics, Inc.. Key Strengths (PTCT)
- Explosive revenue growth of 114.5% YoY with strong 16.5% operating margin demonstrates strong execution
- Approaching profitability with net loss improvement of 287.9% YoY and only -2.8M loss on 272.6M revenue
- Excellent liquidity with 2.44x current ratio and 834M cash providing 3+ years runway at current burn rate
PTCT Stock Risks: Ptc Therapeutics, Inc.. Investment Risks
- Negative stockholders' equity of -180.5M indicates structural insolvency and accumulated losses not yet recovered
- Negative operating cash flow of -59M despite positive operating income suggests non-cash working capital drain or operational cash generation problems
- Negative free cash flow of -60.2M consuming cash reserves; sustainability dependent on near-term profitability inflection
Key Metrics to Watch
- Operating cash flow inflection - must demonstrate positive OCF despite revenue growth
- Time to GAAP net income profitability - appears imminent within 1-2 quarters
- Stockholders' equity recovery trajectory following profitability achievement
- Free cash flow normalization relative to strong operating margins
- Revenue growth sustainability to ensure path to sustained profitability
Ptc Therapeutics, Inc.. (PTCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.44x current ratio provides a solid financial cushion.
PTCT Profit Margin, ROE & Profitability Analysis
PTCT vs Healthcare Sector: How Ptc Therapeutics, Inc.. Compares
How Ptc Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ptc Therapeutics, Inc.. Stock Overvalued? PTCT Valuation Analysis 2026
Based on fundamental analysis, Ptc Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ptc Therapeutics, Inc.. Balance Sheet: PTCT Debt, Cash & Liquidity
PTCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ptc Therapeutics, Inc..'s revenue has grown significantly by 221% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.37 indicates the company is currently unprofitable.
PTCT Revenue Growth, EPS Growth & YoY Performance
PTCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $272.6M | -$2.8M | $-0.03 |
| Q3 2025 | $196.8M | $15.9M | $0.20 |
| Q2 2025 | $178.9M | -$64.8M | $-0.83 |
| Q1 2025 | $210.1M | -$91.6M | $-1.20 |
| Q3 2024 | $196.6M | -$106.7M | $-1.39 |
| Q2 2024 | $186.7M | -$99.2M | $-1.29 |
| Q1 2024 | $210.1M | -$91.6M | $-1.20 |
| Q3 2023 | $196.6M | -$109.3M | $-1.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ptc Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PTCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ptc Therapeutics, Inc.. (CIK: 0001070081)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTCT
What is the AI rating for PTCT?
Ptc Therapeutics, Inc.. (PTCT) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTCT's key strengths?
Claude: Explosive revenue growth of 114.5% YoY with strong 16.5% operating margin demonstrates strong execution. Approaching profitability with net loss improvement of 287.9% YoY and only -2.8M loss on 272.6M revenue.
What are the risks of investing in PTCT?
Claude: Negative stockholders' equity of -180.5M indicates structural insolvency and accumulated losses not yet recovered. Negative operating cash flow of -59M despite positive operating income suggests non-cash working capital drain or operational cash generation problems.
What is PTCT's revenue and growth?
Ptc Therapeutics, Inc.. reported revenue of $272.6M.
Does PTCT pay dividends?
Ptc Therapeutics, Inc.. does not currently pay dividends.
Where can I find PTCT SEC filings?
Official SEC filings for Ptc Therapeutics, Inc.. (CIK: 0001070081) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTCT's EPS?
Ptc Therapeutics, Inc.. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PTCT's fundamental grade?
Based on our AI fundamental analysis in May 2026, Ptc Therapeutics, Inc.. has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PTCT stock overvalued or undervalued?
Valuation metrics for PTCT: ROE of N/A (sector avg: 15%), net margin of -1.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PTCT's AI grade for 2026?
Our dual AI analysis gives Ptc Therapeutics, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PTCT's free cash flow?
Ptc Therapeutics, Inc..'s operating cash flow is $-59.0M, with capital expenditures of $1.2M. FCF margin is -22.1%.
How does PTCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.44 (avg: 2).